SeekingAlpha · Aug 11, 2026
TransMedics Group, Inc. (TMDX) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow
2026-08-11. The following slide deck was published by TransMedics Group, Inc.
TM
NASDAQ · TMDX
TransMedics Group, Inc.
Healthcare · Medical - Devices
$91.75
Down-$0.47 (-0.51%)
Updated Aug 28, 2026, 7:52 AM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.37B
- P/E ratio
- 47.56
- Dividend yield
- 0.00%
- 52-week range
- $60.11 – $135.28
- Volume
- 418.39K
- Avg. volume
- 933.82K
Price performance
TMDX price history
1M range · 21 trading sessions · Daily adjusted prices
TMDX closed at $91.75 after 21 trading sessions, up 20.52% for the selected period.
- Last close
- $91.75
- Period change
- +20.52%
- Period low
- $76.13
- Period high
- $94.77
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $91.59 | $94.24 | $91.13 | $91.75 | 418.39K |
| Aug 26, 2026 | $92.26 | $93.1575 | $90.24 | $92.22 | 448.87K |
| Aug 25, 2026 | $93.62 | $94.33 | $91.5005 | $93.60 | 405.44K |
| Aug 24, 2026 | $94.07 | $94.52 | $92.04 | $93.60 | 770.37K |
| Aug 21, 2026 | $91.11 | $95.18 | $90.445 | $94.77 | 628.72K |
| Aug 20, 2026 | $92.88 | $94.30 | $90.635 | $90.85 | 589.6K |
| Aug 19, 2026 | $90.15 | $94.99 | $90.15 | $93.97 | 703.33K |
| Aug 18, 2026 | $88.45 | $92.50 | $88.45 | $90.69 | 778.3K |
| Aug 17, 2026 | $87.25 | $89.25 | $86.80 | $88.35 | 514.25K |
| Aug 14, 2026 | $90.09 | $90.09 | $87.82 | $88.58 | 434.04K |
| Aug 13, 2026 | $87.02 | $90.05 | $86.985 | $89.64 | 710.23K |
| Aug 12, 2026 | $88.02 | $88.15 | $86.12 | $87.02 | 696.21K |
| Aug 11, 2026 | $87.82 | $89.65 | $85.8101 | $89.36 | 876.74K |
| Aug 10, 2026 | $82.62 | $88.50 | $81.7723 | $88.41 | 1.36M |
| Aug 7, 2026 | $81.00 | $83.98 | $79.51 | $83.89 | 772.37K |
| Aug 6, 2026 | $76.37 | $80.37 | $75.00 | $80.21 | 1.1M |
| Aug 5, 2026 | $72.335 | $77.41 | $68.00 | $76.49 | 2.95M |
| Aug 4, 2026 | $79.838 | $82.11 | $78.8071 | $80.75 | 1.63M |
| Aug 3, 2026 | $78.66 | $83.385 | $77.8901 | $81.55 | 1.52M |
| Jul 31, 2026 | $76.50 | $76.9242 | $74.87 | $76.51 | 532.78K |
| Jul 30, 2026 | $76.15 | $77.90 | $74.03 | $76.13 | 885.01K |
Latest TMDX news
The latest Smart Investors Daily articles mentioning TMDX.
Stock researchCompany · Overview
TMDX research
Overview
Company profile and research snapshot.
Company profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $148.00
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Piper Sandler | Overweight | — |
| Aug 5, 2026 | UBS | Neutral | — |
| Aug 3, 2026 | Needham | Buy | — |
| Jul 28, 2026 | UBS | Neutral | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
TransMedics: Margins Down, Concentration Up, Trials Delayed
TransMedics' Q2 beat driven by low-margin logistics/pricing, liver concentration risk, delayed ENHANCE/DENOVO catalysts, and rich 45x valuation. See more on TMDX.
Benzinga · Aug 5, 2026
UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.
Benzinga · Aug 5, 2026
Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100
Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
